Vinva Investment Management Ltd Sells 518 Shares of Becton, Dickinson and Company (NYSE:BDX)

Vinva Investment Management Ltd trimmed its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 3.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 15,786 shares of the medical instruments supplier’s stock after selling 518 shares during the quarter. Vinva Investment Management Ltd’s holdings in Becton, Dickinson and Company were worth $3,576,000 as of its most recent filing with the SEC.

A number of other large investors have also bought and sold shares of the business. Bank of Jackson Hole Trust bought a new position in shares of Becton, Dickinson and Company during the 4th quarter worth approximately $25,000. Sierra Ocean LLC bought a new position in shares of Becton, Dickinson and Company during the 4th quarter worth approximately $29,000. Picton Mahoney Asset Management grew its stake in shares of Becton, Dickinson and Company by 61.4% during the 4th quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier’s stock worth $32,000 after acquiring an additional 54 shares in the last quarter. Hopwood Financial Services Inc. bought a new position in shares of Becton, Dickinson and Company during the 4th quarter worth approximately $39,000. Finally, Versant Capital Management Inc grew its stake in shares of Becton, Dickinson and Company by 54.1% during the 4th quarter. Versant Capital Management Inc now owns 208 shares of the medical instruments supplier’s stock worth $47,000 after acquiring an additional 73 shares in the last quarter. 86.97% of the stock is owned by institutional investors.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 700 shares of the firm’s stock in a transaction on Wednesday, February 12th. The stock was sold at an average price of $227.99, for a total transaction of $159,593.00. Following the completion of the sale, the director now owns 36,033 shares of the company’s stock, valued at $8,215,163.67. This trade represents a 1.91 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Shana Carol Neal sold 788 shares of the firm’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total value of $185,180.00. Following the sale, the executive vice president now directly owns 16,201 shares of the company’s stock, valued at $3,807,235. This represents a 4.64 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 4,984 shares of company stock valued at $1,147,865 in the last quarter. 0.36% of the stock is currently owned by insiders.

Becton, Dickinson and Company Trading Down 0.1 %

NYSE BDX opened at $231.83 on Thursday. The company has a market cap of $66.57 billion, a PE ratio of 38.51, a PEG ratio of 1.63 and a beta of 0.35. The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $251.99. The stock has a 50 day moving average of $232.68 and a 200-day moving average of $232.12.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. On average, equities research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company announced that its board has authorized a share buyback program on Tuesday, January 28th that permits the company to buyback 10,000,000 shares. This buyback authorization permits the medical instruments supplier to reacquire shares of its stock through open market purchases. Shares buyback programs are typically a sign that the company’s board believes its shares are undervalued.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be issued a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a yield of 1.79%. The ex-dividend date of this dividend is Monday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is 69.10%.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, March 5th. Barclays raised their price target on shares of Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. Finally, Piper Sandler increased their price objective on Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a report on Tuesday, January 28th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $278.29.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.